TY  - JOUR
TI  - Sarcopenia and Frailty Under Teriparatide Treatment: Coincidence or Consequence
AB  - Osteoporosis is characterized by low bone mass andmicro-architectural deterioration of bone tissue and causes increasedfracture risk. In patients diagnosed with osteoporosis, anti-osteoporosis treatment should be arranged. Teriparatide is one of the anabolicdrugs that reduces the risk of vertebral and non-vertebral fractures. Although, muscle weakness was reported as an adverse effect, to our bestknowledge, there is no case presentation that takes attention sarcopeniaas an adverse effect of teriparatide treatment. Sarcopenia is a muscledisorder that is related to adverse outcomes and seen in generally olderpeople. Since the same genetic, mechanical, nutritional and endocrinefactors may be responsible for the age-related muscle and bone loss,recently, the term of osteosarcopenia has been defined. Herein, we reported a case diagnosed with sarcopenia and frailty after teriparatidetreatment and aimed to take attention for the possible relationship between teriparatide and sarcopenia.
AU  - Kara, Ozgur
AU  - Özçakar, Levent
AU  - Ata, Ayşe Merve
AU  - Kara, Murat
DO  - 10.31609/jpmrs.2021-84236
PY  - 2021
JO  - Fiziksel Tıp ve Rehabilitasyon Bilimleri Dergisi
VL  - 24
IS  - 3
SN  - 1309-3843
SP  - 313
EP  - 316
DB  - TRDizin
UR  - http://search/yayin/detay/455250
ER  -